ORMP (Oramed Pharmaceuticals) Marketable Securities : $100.20 Mil (As of Sep. 2024)

View and export this data going back to 2007. Start your Free Trial

What is Oramed Pharmaceuticals Marketable Securities?

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Oramed Pharmaceuticals's Marketable Securities for the quarter that ended in Sep. 2024 was $100.20 Mil.

Oramed Pharmaceuticals's annual Marketable Securities increased from Aug. 2021 ($16.90 Mil) to Dec. 2022 ($115.26 Mil) and increased from Dec. 2022 ($115.26 Mil) to Dec. 2023 ($152.99 Mil).

Oramed Pharmaceuticals Marketable Securities Historical Data

The historical data trend for Oramed Pharmaceuticals's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oramed Pharmaceuticals Marketable Securities Chart

Oramed Pharmaceuticals Annual Data

Trend

Aug14

Aug15

Aug16

Aug17

Aug18

Aug19

Aug20

Aug21

Dec22

Dec23

Marketable Securities

Get a 7-Day Free Trial

28.95

20.60

16.90

115.26

152.99

Oramed Pharmaceuticals Quarterly Data
	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Marketable Securities	Get a 7-Day Free Trial															169.57	152.99	158.02	67.98	100.20

Oramed Pharmaceuticals Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Oramed Pharmaceuticals (NAS:ORMP) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Oramed Pharmaceuticals Marketable Securities Related Terms

Thank you for viewing the detailed overview of Oramed Pharmaceuticals's Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Oramed Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oramed Pharmaceuticals Inc (NAS:ORMP) » Definitions » Marketable Securities

Comparable Companies

Traded in Other Exchanges

ORMP:Israel OJU1:Germany

Address

1185 Avenue of the Americas, Third Floor, New York, NY, USA, 10036

Website

https://www.oramed.com

Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its product pipeline includes ORMD-0801, ORMD-0801, and ORMD 0901.

Executives

Benjamin Shapiro	director	1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK NY 10036
Nadav Kidron	director, 10 percent owner	142 W. 57TH ST., NEW YORK NY 10019
Yadin Rozov	director	9 TERRACE CIRCLE, ARMONK NY 10504
Miriam Kidron	director	2 ELZA STREET, JERUSALEM L3 93706
Michael Rabinowitz	officer: Chief Commercial Officer	1185 AVENUE OF THE AMERICAS, THIRD FLOOR, NEW YORK NY 10036
Arie Mayer	director	MORAN 16, KFAR SABA L3 4428890
Netanel Derovan	officer: Chief Legal Officer	1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK NY 10036
David Silberman	officer: Chief Financial Officer	20 MAMILLA AVENUE, JERUSALEM L3 9414904
Kevin Rakin	director	36 CHURCH LANE, WESTPORT CT 06880
Michael Rabinowitz	officer: Chief Commercial Officer	MAXIM GROUP, LLC, 405 LEXINGTON AVENUE, NEW YORK NY 10174
Leonard Sank	director	3 BLAIR ROAD, CAPE TOWN T3 8005
Gao Xiaoming	director	11F. NO. 266 HANKOU ROAD, HUANGPU DISTRICT, SHANGHAI F4 2000001
Avraham Gabay	officer: CFO, Treasurer and Secretary	2/4 HIGH-TECH PARK, P.O. BOX 39098, JERUSALEM L3 91390
Mark Daniel Hasleton	officer: VP Business Development	13, HIBAT ZION, RAANANA, RAANANA L3 4338111
Aviad Friedman	director	HADASSA 6, TEL AVIV L3 6451306